Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03329378
Title Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai

Her2-receptor positive breast cancer


Docetaxel + Paclitaxel + Pegfilgrastim + Pertuzumab + Trastuzumab

Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.